Metrics to compare | 228760 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship228760PeersSector | |
|---|---|---|---|---|
P/E Ratio | −23.6x | −8.1x | −0.2x | |
PEG Ratio | −11.29 | 0.00 | 0.00 | |
Price/Book | 1.8x | 1.9x | 2.6x | |
Price / LTM Sales | 72.4x | 6.8x | 2.7x | |
Upside (Analyst Target) | - | 39.4% | 66.0% | |
Fair Value Upside | Unlock | 27.0% | 10.8% | Unlock |
Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraDTect SARS-CoV-2 RT-qPCR kits, test providers, and nucleic acid transport medium products. The company was founded in 2000 and is headquartered in Daejeon, South Korea.